The extension granted by Nasdaq is a positive development for Biodexa Pharmaceuticals as it provides the company with additional time to meet the minimum bid price requirement, which is crucial for maintaining its Nasdaq listing. This reduces immediate delisting risk, potentially stabilizing or positively impacting the stock price in the short term.